Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Netarsudil for PVR prevention in RRD
NCT05660447Phase 3Active, not recruiting
- Sponsor
- Wills Eye Hospital
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of netarsudil in Proliferative Vitreoretinopathy (PVR), sponsored by Wills Eye Hospital. Started Feb 2023; status: active, not recruiting.
02
Drugs
netarsudil
03
Conditions
Proliferative Vitreoretinopathy (PVR)
Beyond the preview
Go deeper on NCT05660447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05660447.